Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial - PubMed

Efficacy and safety analyses support deuruxolitinib as a treatment option in adults with AA.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov